Sleep disorders and daytime sleepiness in Parkinson's disease

Current Neurology and Neuroscience Reports

Volumn 9, Issue 2, 2009, Pages 173-180

  Monderer, Renee ^a   Thorpy, Michael ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMFEBUTAMONE; AMITRIPTYLINE; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CAFFEINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CENTRAL STIMULANT AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; DOPAMINE RECEPTOR STIMULATING AGENT; DOXEPIN; ERGOT DERIVATIVE; LEVODOPA; MELATONIN; METHYLPHENIDATE; MODAFINIL; OREXIN; QUETIAPINE; RASAGILINE; SEDATIVE AGENT; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TEMAZEPAM; TRAZODONE; TRIHEXYPHENIDYL; UNINDEXED DRUG; ZALEPLON; ZOLPIDEM;

AGITATION; BEDTIME DOSAGE; BEHAVIOR DISORDER; CARDIOVASCULAR DISEASE; CIRCADIAN RHYTHM SLEEP DISORDER; CLINICAL TRIAL; CONFUSION; DAYTIME SOMNOLENCE; DEPRESSION; DRUG MEGADOSE; DRUG WITHDRAWAL; HALLUCINATION; HEALTH STATUS; HUMAN; HYPERSOMNIA; INSOMNIA; LOW DRUG DOSE; MOTOR DYSFUNCTION; NONREM SLEEP; PARKINSON DISEASE; POLYSOMNOGRAPHY; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; REM SLEEP; RESTLESS LEGS SYNDROME; REVIEW; SIDE EFFECT; SLEEP DISORDER; UNPLEASANT DREAM; WAKEFULNESS; ARTICLE; FEMALE; MALE; PATHOPHYSIOLOGY; SOMNOLENCE;

DISORDERS OF EXCESSIVE SOMNOLENCE; FEMALE; HUMANS; MALE; PARKINSON DISEASE; POLYSOMNOGRAPHY; SLEEP DISORDERS;

EID: 62649128032     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-009-0026-5     Document Type: Review

References (80)

1. Lees AJ, Blackburn NA, Campbell VL: The nighttime problems of Parkinson's disease. Clin Neuropharmacol 1988, 11:512-519.
2. Tandberg E, Larsen JP, Karlsen K: A community-based study of sleep disorders patients with Parkinson's disease. Mov Disord 1998, 13:895-899.
3. Diederich NJ, Vaillant M, Mancuso G, et al.: Progressive sleep 'destructuring' in Parkinson's disease. A polysomnographic study in 46 patients. Sleep Med 2005, 6:313-318.
4. Borek LL, Kohn R, Friedman JH: Md and sleep in Parkinson's disease. J Clin Psychiatry 2006, 67:958-963.
5. Kumar S, Bhatia M, Behari M: Sleep disorders in Parkinson's disease. Mov Disord 2002, 17:775-781.
6. Gneratne NS, Weaver TE, Carter JR, et al.: Functional outcomes of excessive daytime sleepiness in older adults. J Am Geriatr Soc 2003, 51:642-649.
7. Gjerstad MD, Wentzel-Larsen T, Aarsland D, Larsen JP: Insomnia in Parkinson's disease: Frequency and progression over time. J Neurol Neurosurg Psychiatry 2007, 78:476-479.
8. Plazzi G: REM sleep behavior disorders in Parkinson's disease and other Parkinson's disorders. Sleep Med 2004, 5:195-199.
9. Arnulf I: Excessive daytime somnolence in parkinsonism. Sleep Med Rev 2005, 9:185-200.
10. Montastruc JL, Brefel-Courban C, Senard JM, et al.: Sleep attacks and antiparkinsonian drugs: A pilot prospective pharmacoepidemiologic study. Clin Neuropharmacol 2001, 24:181-183.
11. Wetter TC, Trenkwalder C, Gershanik O, Hogl B: Polysomnographic measures in Parkinson's disease: A comparison between patients with and without REM sleep disturbances. Wien Klin Wochenschr 2001, 113:249-253.
12. Shpirer I, Minovitz A, Klein C, et al.: Excessive daytime sleepiness in patients with Parkinson's disease: A polysomnography study. Mov Disord 2006, 21:1432-1438.
13. Friedman A: Sleep pattern in Parkinson's disease. Acta Med Pol 1980, 21:193-199.
14. Brunner H, Wetter TC, Hogl B, et al.: Microstructure of the non-rapid eye movement sleep electroencephalogram in patients with newly diagnosed Parkinson's disease: Effects of dopaminergic treatment. Mov Disord 2002, 17:928-933.
15. Scaglione C, Vignatelli L, Plazzi G, et al.: REM sleep behavior disorder in Parkinson's disease: A questionnaire-based study. Neurol Sci 2005, 25:316-321.
16. Eisensehr I, von Lindeiner H, Jager M, et al.: REM sleep behavior disorder in sleep-disordered patients with versus without Parkinson's disease: Is there a need for polysomnography? J Neurol Sci 2001, 186:7-11.
17. Nass A, Nass RD: Actigraphic evidence for night-time hyperkinesias in Parkinson's disease. Int J Neurosci 2008, 118:291-310.
18. Lee MS, Rinne JO, MarsdeI CD: The pedunculopontine nucleus: its role in the genesis of movement disorders. Yonsei Med J 2000, 41:167-184.
19. Fronczek R, Overeem S, Lee SY, et al.: Hypocretin (orexin) loss in Parkinson's diasease. Brain 2007, 130:1577-1585.
20. Thannickal TC, Lai YY, Siegel JM: Hypocretin (orexin) cell loss in Parkinson's disease. Brain 2007, 130:1586-1595.
21. Yasui K, Inoue Y, Kanbayashi T, et al.: CSF orexin levels in Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci 2006, 250:120-123.
22. Zoltoski RK, Velazquez-Moctezuma J, Shiromani PJ, et al.: The relative effects of selective M1 muscarinic antagonists on rapid eye movement sleep. Brain Res 1993, 608:186-190.
23. Garcia-Borreguero D, Caminero AB, de la Llave Y, et al.: Decreased phasic EMG activity during rapid eye movement sleep in treatment of naive Parkinson's disease: Effects of treatment with levodopa and progression of illness. Mov Disord 2002, 17:934-941.
24. Rye DB: Parkinson's disTase and RLS: the dopaminergic bridge. Sleep Med 2004, 5:317-328.
25. Gjerstad MD, Alves G, Wentzel-Larsen T, et al.: Excessive daytime sleepiness in Parkinson's disease: Is it the drugs or the disease? Neurology 2006, 6:853-858.
26. Kaynak D, Kiziltan G, Kaynak H, et al.: Sleep and sleepiness in patients with Parkinson's disease before and after dopaminergic treatment. Eur J Neurol 2005, 12:199-207.
27. Razmy A, Lang AE, Shapiro CM: Predictors of impaired daytime sleep and wakefulness in patients with Parkinson's disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol 2004, 61:97-102.
28. Kurth MC, Adler CH, Hilaire MS, et al.: Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 1997, 48:81-87.
29. Hublin C, Partinen M, Heinonen EH, et al.: Selegiline in the treatment of narcolepsy. Neurology 1994, 44:2095-2101.
30. Thorton C, Dore CJ, Elsworth JD, et al.: The effect of deprenyl, a selective monoamine oxidase B inhibitor, on sleep and md in man. Psychopharmacology 1980, 70:163-166.
31. Schapira AH: Progress in neuroprotection in Parkinson's disease. Eur J Neurol 2008, 15(Suppl 1):5-13.
32. Cicolin A, Lopiano L, Zibetti M, et al.: Effects of deep brain stimulation of the subthalamic nucleus on sleep architecture in parkinsonian patients. Sleep Med 2004, 5:207-210.
33. Lyons K, Pahwa R: Effects of bilateral subthalamic nucleus stimulation on sleep, daytime sleepiness, and early morning dystonia in patients with Parkinson's disease. J Neurosurg 2006, 104:502-505.
34. Zibetti M, Torre E, Cinquepalmi A, et al.: Motor and nonmotor symptom follow-up in parkinsonian patients after deep brain stimulation of the subthalamic nucleus. Eur Neurol 2007, 58:218-223.
35. Ghorayeb I, Loundou A, Auquier P, et al.: A nationwide survey of excessive daytime sleepiness in Parkinson's disease in France. Mov Disord 2007, 22:1567-1572.
36. Boddy F, Rowan EN, Lett D, et al.: Subjectively reported sleep quality and excessive daytime somnolence in Parkinson's disease with and without dementia, dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry 2007, 22:529-535.
37. Wegelin J, McNamara P, Durso R, et al.: Correlates of excessive daytime sleepiness in Parkinson's disease. Parkinsonism Rel Disord 2005, 11:441-448.
38. Monaca C, Duhamel A, Jacquesson JM, Ozsancak C, et al.: Vigilance troubles in Parkinson's disease: A subjective and objective polysomnographic study. Sleep Med 2006, 7:448-453.
39. Korner Y, Meindorfner C, Moller JC, et al.: Predictors of sudden onset of sleep. Mov Disord 2004, 19:1298-1305.
40. Manni R, Terzaghi M, Sartori I, et al.: Dopamine agonists and sleepiness in PD: Review of the literature and personal findings. Sleep Med 2003, 5:189-193.
41. Rissling I, Geller F, Bandmann O, et al.: Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting "sleep attacks." Mov Disord 2004, 19:1279-1284.
42. Rissling I, Körner K, Geller F, et al.: Preprohypocretin polymorphism in Parkinson's disease patients reporting "sleep attacks." Sleep 2005, 28:871-875.
43. Meindorfner C, Korner Y, Moller JC, et al.: Driving in Parkinson's disease: Mobility, accidents, and sudden onset of sleep at the wheel. Mov Disord 2005, 20:832-842.
44. Uc EY, Rizzo M, Anderson SW, et al.: Driving with distraction in Parkinson's disease. Neurology 2006, 67:1774-1780.
45. Comella CL: Sleep disturbances in Parkinson's disease. Curr Neurol Neurosci Rep 2003, 3:173-180.
46. Hogl B, Saletu M, Brandauer E, et al.: Modafinil for the treatment of daytime sleepiness in Parkinson's disease: A double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002, 25:905-909.
47. Adler CH, Caviness JN, Hentz JG, et al.: Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 2003, 18:287-293.
48. Ondo WG, Fayle R, Atassi F, et al.: Modafinil for daytime somnolence in Parkinson's disease: Double blind, placebo controlled prallel trial. J Neurol Neruosurg Psychiatry 2005, 76:1636-1639.
49. Brga-Neto P, da Silva-Junior FP, Sueli Monte F, et al.: Snoring and excessive daytime sleepiness in Parkinson's disease. J Neurol Sci 2004, 217:41-45.
50. Arnulf I, Konofal E, Merino-Andreu M, et al.: Parkinson's disease and sleepiness; an integral part of PD. Neurology 2002, 58:1019-1024.
51. Diederich NJ, Vaillant M, Leischen M, et al.: Sleep apnea syndrome in Parkinson's disease. A case control study in 49 patients. Mov Disord 2005, 20:1413-1418.
52. Juri C, Chaná P, Tapia J, et al.: Quetiapine for insomnia in Parkinson disease: Results from an open-label trial. Clin Neuropharmacol 2005, 28:185-187.
53. Kunz D, Bes F: Melatonin as a therapy in REM sleep behavior disorder patients: An open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation. Mov Disord 1999, 14:507-511.
54. Gomez-Esteban JC, Zarranz JJ, Tijero B, et al.: Restless legs syndrome in Parkinson's disease. Mov Disord 2007, 22:1912-1916.
55. Nomura T, Inoue Y, Miyake M, et al.: Prevalence and clinical characteristics of restless legs syndrome in Japanese patients with Parkinson's disease. Mov Disord 2006, 21:380-384.
56. Loo HV, Tan EK: Case-control study of restless legs syndrome and quality of sleep in Parkinson's disease. J Neurol Sci 2008, 266:145-149.
57. Nomura T, Inoue Y, Nakashima K: Clinical characteristics of restless legs syndrome in patients with Parkinson's disease. J Neurol Sci 2006, 250:39-44.
58. Happe S, Pirker W, Kloch G, et al.: Periodic leg movements in patients with Parkinson's disease are associated with reduced striatal dopamine transporter binding. J Neurol 2003, 250:83-86.
59. Michaud M, Soucy JP, Chabli A, et al.: SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep. J Neurol 2002, 249:164-170.
60. Ruottinen HM, Partinen M, Hublin C, et al.: An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology 2000, 54:502-504.
61. Allen R: Dopamine and iron in the pathophysiology of restless legs syndrome. Sleep Med 2004, 5:385-391.
62. Pacchetti C, Manni R, Zangaglia R, et al.: Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease. Mov Disord 2005, 20:1439-1448.
63. Hickey MG, Demaerschalk BM, Caselli RJ, et al.: "Idiopathic" rapid-eye-movement sleep behavior disorder is associated with future development of neurodegenerative diseases. Neurologist 2007, 13:98-101.
64. Irazno A, Santamaria J, Rye DB, et al.: Characteristics of REM sleep behavior disorder and that associated with MSA and PD. Neurology 2005, 65:247-252.
65. Borek LL, Kohn R, Friedman JH: Phenomenology of dreams in Parkinson's disease. Mov Disord 2007, 22:198-202.
66. Gjerstad MD, Boeve B, Wentzel-Larsen T, et al.: Occurrence of clinical correlates of REM sleep behavior disorder in patients with Parkinson's disease over time. J Neurol Neurosurg Psychiatry 2008, 79:387-391.
67. Vendette M, Gagnon JF, Decary A, et al.: REM sleep behavior predicts cognitive impairment in Parkinson disease without dementia. Neurology 2007, 69:1843-1849.
68. Tan A, Salgado M, Fahn S: Rapid eye movement sleep behavior disorder preceding Parkinson's disease with therapeutic response to levodopa. Mov Disord 1996, 11:214-216.
69. Boeve BF, Silber MH, Ferman TJ: Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: Results in 14 patients. Sleep Med 2003, 4:281-284.
70. Bruguerolle B, Simon N: Biologic rhyAhms and Parkinson's disease: a chronopharmacological approach to considering fluctuations in function. Clin Neuropharmacol 2002, 25:194-201.
71. Willis GL, Turner EJ: Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light: A case series study. Chronobiol Int 2007, 24:521-537.
72. Paus S, Schmitz-Hubsch T, Wullner U, et al.: Bright light therapy in Parkinson's disease: A pilot study. Mov Disord 2007, 22:1495-1498.
73. Dowling GA, Mastick J, Colling E, et al.: Melatonin for sleep disturbances in Parkinson's disease. Sleep Med 2005, 6:459-466.
74. Medeiros CA, Carvalhedo de Bruin PR, Lopes LA, et al.: Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease: A randomized, double blind, placebo-controlled study. J Neurol 2007, 254:459-464.
75. Srinivasan V, Pandi-Perumal S, Cardinali D, et al.: Melatonin in Alzheimer's disease and other neurodegenerative disorders. Behav Brain Funct 2006, 2:15.
76. Tesei S, Antonini A, Canesi M, et al.: Tolerability of paroxetine in Parkinson's disease: A prospective study. Mov Disord 2000, 15:986-989.
77. Cummings JL: Managing psychosis in patients with PaAkinson's disease: a review. N Engl J Med 1999, 240:801-803.
78. Fernandez HH, Trieschmann ME, Burke MA, et al.: Long-term outcome of quetiapine use for psychosis among parkinsonian patients. Mov Disord 2003, 18:510-514.
79. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ: Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonian Relat Disord 2002, 8:193-197.
80. Shulman LM, Wen X, Weiner WJ, et al.: Acupuncture therapy for the symptoms of Parkinson's disease. Mov Disord 2002, 17:799-802.